FI77847C - Foerfarande foer framstaellning av terapeutiskt anvaendbara alkensyraderivat. - Google Patents

Foerfarande foer framstaellning av terapeutiskt anvaendbara alkensyraderivat. Download PDF

Info

Publication number
FI77847C
FI77847C FI822205A FI822205A FI77847C FI 77847 C FI77847 C FI 77847C FI 822205 A FI822205 A FI 822205A FI 822205 A FI822205 A FI 822205A FI 77847 C FI77847 C FI 77847C
Authority
FI
Finland
Prior art keywords
ester
preparation
acid derivatives
formula
therapeutically useful
Prior art date
Application number
FI822205A
Other languages
English (en)
Swedish (sv)
Other versions
FI822205L (fi
FI822205A0 (fi
FI77847B (fi
Inventor
Alec Todd
Stephen Richard Baker
William Boffey Jamieson
William James Ross
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI822205A0 publication Critical patent/FI822205A0/fi
Publication of FI822205L publication Critical patent/FI822205L/fi
Publication of FI77847B publication Critical patent/FI77847B/fi
Application granted granted Critical
Publication of FI77847C publication Critical patent/FI77847C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B45/00—Formation or introduction of functional groups containing sulfur
    • C07B45/04—Formation or introduction of functional groups containing sulfur of sulfonyl or sulfinyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C07F9/5304—Acyclic saturated phosphine oxides or thioxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

χ 77847
Menetelmä terapeuttisesti käyttökelpoisten alkeenihappo-johdannaisten valmistamiseksi
Keksinnön kohteena on menetelmä farmaseuttisesti 5 aktiivisen yhdisteen valmistamiseksi, jolla on kaava
OH
I COOZ1 C11H23CH=CHNAV^^^ T CH3 ^^NHCOCH3
10 S-C-CH
^H^^COOZ2 1 2 jossa Z ja Z kumpikin on vety, alkalimetalli tai alempi alkyyli.
15 Yhdisteet ovat farmaseuttisesti aktiivisia SRS-A:n antagonisteina.
Läheisiä yhdisteitä tunnetaan mm. EP-hakemusjulkaisusta 36 663 sekä julkaisuista J. of American Chem. Soc. 102 (1980) s. 1436-39 (erityisesti s. 1438 kaava 17) ja 20 Chem. Abstr. 94 (1981), 154001 d sekä Chem. Abstr. 95 (1981), 59785 z.
Keksinnön mukaiset yhdisteet valmistetaan siten, että yhdiste, jolla on kaava . C11H23CH=CH—-—CH^^-^^COOH (IV) tai sen suola tai esteri saatetaan reagoimaan tiolin kanssa, jolla on kaava 30 CH3 ___^nhcoch3 - (V)
“ I "''•-COOH
C2H5 35 Δ 5 tai sen suolan tai esterin kanssa, 2 77847 minkä jälkeen esteriryhmä/esteriryhmät haluttaessa hydrolysoidaan .
Menetelmä suoritetaan vahvan emäksen (pKa<12), kuten trialkyyliamiinin, esim. trietyyliamiinin läsnäollessa 5 ja inertissä polaarisessa liuottimessa, kuten alkanolissa, esim. metanolissa. Sopiva reaktiolämpötila on 10° - 50°C, edullisesti huoneenlämmössä. Reaktiota voidaan katalysoida adsorboimalla kaavan (V) mukainen tioli aktiiviseen alumiinioksidiin .
10 Menetelmässä on edullista käyttää yhdistettä (IV) esterimuodossa, edullisesti C^_4-alkyyliesterimuodossa ja erikoisesti metyyliesterimuodossa. Keksinnön mukainen yhdiste valmistetaan siten aluksi vastaavassa esterimuodossa.
Tässä reaktiossa isomeerinen 5-tio-6-hydroksiyhdis-15 te voi muodostua samalla kun haluttu 5-hydroksi-6-tio- yhdiste. Isomeerinen sivutuote voidaan poistaa seoksesta happomuodon muodostuksella, jota seuraa laktonisaatio, esim. kuumentamalla inertissä luottimessa kuten tolueenis-sa ja vain 5-hydroksi-yhdiste läpikäy laktonisaation.
20 Saadut keksinnön mukaiset yhdisteet voidaan erot taa ja puhdistaa tavanomaisesti.
Keskinäinen muuttaminen useiden keksinnön mukaisten yhdisteiden muotojen välillä, esim. suola-, vapaa happo- ja esterimuotojen välillä voidaan suorittaa tavanomai-25 sesti. Esimerkiksi esterimuodot voidaan muuttaa suolamuo-doiksi käsittelemällä sopivalla vesipitoisella laimealla emäksellä pH-arvossa 9-10. Suolamuodot voidaan muuttaa vapaiksi happomuodoiksi hapon muodostuksella vesipitoisessa väliaineessa. Suola- tai vapaat happomuodot voidaan 30 muuttaa esterimuodoiksi emäksen tai hapon katalysoimalla esteröinnillä käyttäen sopivaa alkoholia. Välituoteyhdis-teet ovat joko tunnettuja tai ne voidaan valmistaa saatavissa olevista lähtöaineista tavanomaisesti.
Kaavan (IV) mukaiset epoksidit voidaan valmistaa 35 hapettamalla kaavan (II) mukaisia yhdisteitä
C11H23CH=CH>^^\^^>S\ COOK
3 77847 edullisesti esterimuodossa käyttäen hapettimena m-kloori-perbentsoehappoa tai vetyperoksidia. Kun hapettimena käytetään m-klooriperbentsoehappoa, hapetus suoritetaan kloroformissa ja kun käytetään vetyperoksidia# hapetus suori-5 tetaan metanolissa.
Keksinnön mukaiset yhdisteet ovat farmaseuttisesti aktiivisia SRS-A:n antagonisteina, kuten on osoitettu seuraavilla kokeilla: in vitro kokeella marsun sykkyräsuo-lisegmentillä väkevyyksissä 10-50 yug julkaisussa Schild, 10 1947 Brit. J. Pharm. 2 197-206 kuvatun menetelmän mukaan (keksinnön mukaisilla yhdisteillä ICj-q SRS-A:ta vastaan on alle 10 4 moolia); in vivo marsun keuhkotoimintakokeel-la (Austen ja Drazen 1974 J. Clin. Invest. 53:1679-1685) laskimonsisäisillä annospitoisuuksilla 0,05 yug - 5,0 mg/kg 15 ja modifioidussa "Herxheimer"-kokeessa annospitoisuuksilla 25-200 mg/kg. "Herxheimer"-koe perustuu marsuihin aikaansaatuun allergiseen keuhkoputken kouristukseen, joka läheisesti muistuttaa astmaattista kohtausta ihmisellä. Keuhkoputken kouristuksen aiheuttavat mediaattorit ovat 20 hyvin samanlaisia kuin ne, jotka vapautuvat kun ihmisen herkistettyyn keuhkokudokseen vaikuttaa antigeeni. Modifioidussa kokeessa, jota käytettiin keksinnön mukaisilla yhdisteillä, eläimet esikäsiteltiin histamiinin antagonistilla, mepyramiinilla aluksi annospitoisuudella 0,5 mg/kg 25 30 min ennen varsinaista annostusta. Tämä modifikaatio peittää histamiinin vaikutuksen niin että SRS-A:n vaikutus tulee paremmin esille.
Esimerkin 1 mukaisen yhdisteen IC^-arvo SRS-A:ta vastaan marsun sykkyräsuolikokeessa (Schild, Brit. J.
30 Pharm. 2 (1947) 197-206) oli 10 ^ ja esimerkin 2 mukaisen -5 yhdisteen 10
Yhdisteet ovat niin ollen sopivia terapeuttista käyttöä varten hoidettaessa keuhkojärjestelmän allergisia reaktioita, joissa SRS-A:ta pidetään keuhkoputken kouris-• · 35 tusta aiheuttavana mediaattorina, so. allergisissa keuhko sairauksissa kuten ulkosyntyisessä astmassa ja teollisuus- A 77847 4 astmoissa kuten maanviljelijän ja kyyhkyskasvattajän keuhkoastmassa, samoin kuin muissa allergisissa sairauksissa, tulehdussairauksissa tai keuhkosairauksissa, joissa SRS-A:ta pidetään mediaattorina.
5 Aktiiviset yhdisteet ovat tehokkaita laajalla an- nostusalueella ja esimerkiksi päivittäiset annostukset ovat 0,5-300 mg/kg, useimmiten 5-100 mg/kg.
Seuraavat esimerkit valaisevat keksintöä.
Esimerkki 1 10 (a) (DL-N-asetyyli-3-merkaptoisoleusyyli)glysiinimetyy- liesteri
Etyyliklooriformaatti (0,12 ml) lisätään sekoitettuun liuokseen, jossa on DL-N-asetyyli-3-merkapto-isoleu-siiniä (0,20 g) dikloorimetaanissa (10 ml) ja trietyyli-15 amiinia (0,28 ml) -10°C:ssa. Liuoksen annetaan lämmetä huoneenlämpöön, pestään laimealla suolahapolla ja sen jälkeen natriumbikarbonaattiliuoksella, kuivataan ja haihdutetaan, jolloin saadaan 3-asetamido-4-etyyli-4-metyyli-2-tioetanoni vaaleana öljynä.
20 Tämän tiolaktonin liuokseen dikloorimetaanissa (5 ml) lisätään kiinteää glysiinimetyyliesterihydrokloridia (0,15 g) ja trietyyliamiinia (0,20 ml) ja seosta sekoitetaan 16 tuntia. Kirkas liuos pestään laimealla suolahapolla ja sen jälkeen natriumbikarbonaattiliuoksella, kuiva-25 taan ja haihdutetaan ja jäännös kiteytetään metanoli-ve-*: destä, jolloin saadaan otsikoitu yhdiste, sp. 136°C.
(b) 5- (S) -hydroksi-6 (R) -Z.T2- (N-asetyyliamino) -2-metok- sikarbonyyli-l-etyyli-l-metyylietyyli)-tiQ/-7-(Z)-nonadekeenihappo ja sen 5-(R)-6-(S)-isomeeri 30 Metyyli-5,6-(E)-oksido-7-(Z)-nonadekenoaatin (162 mg) annetaan reagoida 50°C:ssa 3-4 päivää liuoksen \ kanssa, jossa oli DL-N-asetyyli--merkaptoisoleusiinime- tyyliesteriä (216 mg) ja trietyyliamiinia (200 ^ul) kuivas-; sa metanolissa (500 pl). Kun metanoli on poistettu typpi- 35 virran avulla, jäännös liuotetaan seokseen, jossa on di-etyylieetteri-heksaania 50/50 v/v ja kromatografoidaan 5 77847 käyttäen silikageeliä. Kehittäminen samalla liuotinseok-sella antoi aluksi reagoimattoman epoksidin. Edelleen eluoiminen dikloorimetaani/metanolin 95/5 v/v seoksen kanssa antaa halutun dimetyyliesterin, joka sisältää epäpuh-5 tautena vähän vapaata tiolia, vaaleankeltaisena öljynä.
Sen jälkeen dimetyyliesteri liuotetaan metanoliin (3 ml) ja lisätään 2 M natriumkarbonaattiliuosta (1,5 ml) ja muutama pisara vettä, jolloin saadaan samea liuos. Hydrolyy-sin annetaan jatkua huoneenlämmössä 3 päivää, jonka jäl-10 keen melkein kirkas liuos tehdään varovasti happameksi pH-arvoon 3,5 (käyttäen laimeaa suolahappoa) ja uutetaan dikloorimetaanilla. Yhdistetyt uutteet pestään vedellä, kuivataan magnesiumsulfaatilla ja haihdutetaan tyhjössä, jolloin saadaan otsikoitu yhdiste vaaleankeltaisena vis-15 koosina öljynä.
Esimerkki 2 5- (S) -hydroksi-6- (R) -Z_l2- (N-asetyyliamino) -2-karb-oksi-l-etyyli-l-metyylietyyli)tig7-7-(Z)-nonadekee-nihappo ja sen 5-(R)-6-(S)-isomeeri 20 Esimerkin 1 monometyyliesteri (89 mg) liuotetaan tetrahydrofuraaniin (4 ml) ja lisätään 4 M litiumhydroksi-diliuosta (1 ml) ja sen jälkeen edelleen vettä (3 ml), jolloin saadaan homogeeninen liuos, jota kuumennetaan 48°C:ssa 4 päivän ajan. Tetrahydrofuraani poistetaan haih-25 duttamalla tyhjössä ja jäännös jaetaan dikloorimetaanin ja veden kesken pH-arvossa 3 (säädetty laimealla suolahapolla) . Dikloorimetaaniuute kuivataan magnesiumsulfaatilla ja haihdutetaan typpivirrassa, jolloin saadaan haluttu dikarboksyylihappo värittömänä viskoosina öljynä.

Claims (3)

  1. 6 77847 Patenttivaatimus Menetelmä farmaseuttisesti aktiivisen yhdisteen valmistamiseksi, jolla on kaava
  2. 5 OH I COOZ1 C H?1CH=CH 1. ch3 ^^nhcoch3 S-C-CH^ J^—COOZ^
  3. 10 C2H5 1 . 2 jossa Z ja Z kumpikin on vety, alkalimetalli tai alempi alkyyli, tunnettu siitä, että yhdiste, jolla on kaava 15 ^ C11H 2<3Η-(ίΗ--CH * COOH (IV) tai sen suola tai esteri saatetaan reagoimaan tiolin kanssa, jolla on kaava 20 ^Η3 ^^^NHCOCH3 HS-C -ClC" (V) I ^^-COOH C2H5 25 tai sen suolan tai esterin kanssa, minkä jälkeen esteriryhmä/esteriryhmät haluttaessa hydrolysoidaan .
FI822205A 1981-06-18 1982-06-18 Foerfarande foer framstaellning av terapeutiskt anvaendbara alkensyraderivat. FI77847C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8118720 1981-06-18
GB8118720 1981-06-18
GB8213211 1982-05-07
GB8213211 1982-05-07

Publications (4)

Publication Number Publication Date
FI822205A0 FI822205A0 (fi) 1982-06-18
FI822205L FI822205L (fi) 1982-12-19
FI77847B FI77847B (fi) 1989-01-31
FI77847C true FI77847C (fi) 1989-05-10

Family

ID=26279835

Family Applications (1)

Application Number Title Priority Date Filing Date
FI822205A FI77847C (fi) 1981-06-18 1982-06-18 Foerfarande foer framstaellning av terapeutiskt anvaendbara alkensyraderivat.

Country Status (23)

Country Link
US (1) US4513005A (fi)
EP (1) EP0068739B1 (fi)
KR (1) KR890000622B1 (fi)
AU (1) AU549814B2 (fi)
BG (1) BG37226A3 (fi)
CA (1) CA1224795A (fi)
CS (1) CS241109B2 (fi)
DD (1) DD202697A5 (fi)
DE (1) DE3261237D1 (fi)
DK (1) DK271682A (fi)
ES (3) ES8307212A1 (fi)
FI (1) FI77847C (fi)
GB (1) GB2101594B (fi)
GR (1) GR76838B (fi)
HU (1) HU192105B (fi)
IE (1) IE53522B1 (fi)
IL (1) IL66056A0 (fi)
NZ (1) NZ200984A (fi)
PH (1) PH23051A (fi)
PL (4) PL137766B1 (fi)
PT (1) PT75058B (fi)
RO (1) RO83706B (fi)
ZA (1) ZA824294B (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4537723A (en) * 1982-02-04 1985-08-27 The Upjohn Company Derivatives of leukotrienes A and C
US4775662A (en) * 1983-03-07 1988-10-04 Smithkline Beckman Corporation Leukotriene antagonists
DK130984A (da) * 1983-03-07 1984-09-08 Smithkline Beckman Corp Leukotrien-antagonister
DE3469169D1 (en) * 1983-04-21 1988-03-10 Merck Frosst Canada Inc Leukotriene antagonists, their production and use and compositions containing them
US4609744A (en) * 1983-04-21 1986-09-02 Merck Frosst Canada Inc. 4-oxo-benzopyran carboxylic acids
US5017583A (en) * 1983-04-21 1991-05-21 Merck Frosst Canada, Inc. Leukotriene antagonists
US4720505A (en) * 1983-06-27 1988-01-19 Merck Frosst Canada, Inc. Leukotriene antagonists
GB8320943D0 (en) * 1983-08-03 1983-09-07 Lilly Industries Ltd Organic compounds
AU572615B2 (en) 1983-12-27 1988-05-12 Sony Corporation Electrically conductive adhesive sheet circuit board and electrical connection structure
CA1288107C (en) * 1983-12-27 1991-08-27 Yves Girard Leukotriene antagonists
US4761425A (en) * 1983-12-27 1988-08-02 Merck Frosst Canada, Inc. Leukotriene antagonists
US4769386A (en) * 1984-06-18 1988-09-06 Smithkline Beckman Corporation Imidazolylthioalkenoic acids and -alkenols and leukotriene antagonistic composition containing them
EP0170048B1 (de) * 1984-06-28 1991-04-17 Ciba-Geigy Ag Aliphatische Thioether
US4889873A (en) * 1984-07-18 1989-12-26 Schering Corporation Inhibitors of slow reacting substance of anaphylaxis
US4758594A (en) * 1984-07-18 1988-07-19 Schering Corporation Inhibitors of slow reacting substance of anaphylaxis
US4798842A (en) * 1984-07-18 1989-01-17 Schering Corporation Inhibitors of slow reacting substance of anaphylaxis
US4988716A (en) * 1984-07-18 1991-01-29 Schering Corporation Inhibitors of slow reacting substance of anaphylaxis
GB8502258D0 (en) * 1985-01-30 1985-02-27 Lilly Industries Ltd Organic compounds
US4874792A (en) * 1985-04-19 1989-10-17 Smithkline Beckman Corporation Thiophenyl Alkanoic acids useful as leukotriene antagonists
US4937253A (en) * 1985-04-19 1990-06-26 Smithkline Beecham Corporation Ester prodrugs
AU595193B2 (en) * 1985-04-19 1990-03-29 Smithkline Beckman Corporation Thio substituted acidic derivatives
US4939279A (en) * 1985-04-19 1990-07-03 Smithkline Beecham Corporation Leukotriene antagonists
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
US4990526A (en) * 1985-06-18 1991-02-05 Merck Frosst Canada, Inc. Leukotriene antagonists, compositions and methods of use thereof
US4696946A (en) * 1985-08-30 1987-09-29 Schering Corporation Topical Treatment of hyperproliferative skin diseases
US4783483A (en) * 1985-10-03 1988-11-08 Ortho Pharmaceutical Corporation Epoxides useful as antiallergic agents
FI864901A (fi) * 1985-12-06 1987-06-07 Ciba Geigy Ag Hydroxitioetrar.
KR870011086A (ko) * 1986-05-29 1987-12-19 벤자민 에프. 램버트 포스포리파제 a₂억제제 및 그의 합성방법
GB8709547D0 (en) * 1987-04-22 1987-05-28 Lilly Industries Ltd Organic compounds
DE3724669A1 (de) * 1987-07-25 1989-02-02 Hoechst Ag Leukotrienantagonisten, verfahren zu ihrer herstellung und ihre anwendung zur behandlung von krankheiten
DE3724735A1 (de) * 1987-07-25 1989-02-02 Hoechst Ag Leukotrienantagonisten, verfahren zu ihrer herstellung, ihre anwendung zur behandlung von krankheiten, sowie vorprodukte
GB8725260D0 (en) * 1987-10-28 1987-12-02 Lilly Industries Ltd Organic compounds
AU610528B2 (en) * 1987-10-29 1991-05-23 Smithkline Beckman Corporation Leukotriene antagonists
GB8807016D0 (en) * 1988-03-24 1988-04-27 Lilly Industries Ltd Organic compounds & their pharmaceutical use
US5073571A (en) * 1988-06-16 1991-12-17 Washington University Method of inhibiting virus
US4954513A (en) * 1988-12-23 1990-09-04 Smithkline Beecham Corporation Leukotriene antagonists
US5149835A (en) * 1989-04-27 1992-09-22 University Of New Mexico Substituted mevalonolactones, and methods for stereoselective preparation thereof and desmethyl homologues thereof
EP0410244A1 (en) * 1989-07-27 1991-01-30 Bayer Ag Leukotriene antagonists
US5238683A (en) * 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
WO1991017149A1 (en) * 1990-05-01 1991-11-14 Smithkline Beecham Corporation 3-naphthyl-3-carboxyalkylthio or oxy substituted alkanoic acid leukotriene antagonists
US8026280B2 (en) * 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US20030212191A1 (en) * 2002-04-15 2003-11-13 Nippon Bee Chemical Co., Ltd. Aqueous primer coating composition, process for formation of coating film using said composition, and coated article
EP1511477A4 (en) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
JP5289707B2 (ja) * 2004-08-31 2013-09-11 住友ベークライト株式会社 オキシルアミノ基含有化合物
US20060160902A1 (en) * 2004-11-08 2006-07-20 Wiech Norbert L Histone deacetylase inhibitors
US7754838B2 (en) * 2006-08-08 2010-07-13 E.I. Du Pont De Nemours And Company Poly(meth)acrylamides and poly(meth)acrylates containing fluorinated amide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177227A (en) * 1963-01-30 1965-04-06 Shell Oil Co Lactone production
DE2945497A1 (de) * 1979-03-06 1980-10-09 Degussa Derivate der d-2-hydroxy-4-methylmercaptobuttersaeure, verfahren zu deren herstellung und deren verwendung
US4311645A (en) * 1980-03-24 1982-01-19 Hoffmann-La Roche Inc. Synthesis of SRS-active compounds
FR2479213A1 (fr) * 1980-03-28 1981-10-02 Roussel Uclaf Procede de preparation d'acide pentenoique possedant une fonction aldehyde
JPS57118555A (en) * 1981-01-13 1982-07-23 Ono Pharmaceut Co Ltd Leucotriene-analog compound, its preparation, and leucotriene-biosynthesis inhibiting agent containing said compound as active component
US4352757A (en) * 1981-02-02 1982-10-05 Smithkline Beckman Corporation Process for the preparation of esters of leukotriene A

Also Published As

Publication number Publication date
DE3261237D1 (en) 1984-12-20
DD202697A5 (de) 1983-09-28
AU549814B2 (en) 1986-02-13
IL66056A0 (en) 1982-09-30
PL240484A1 (en) 1983-09-12
ES513221A0 (es) 1983-07-01
CA1224795A (en) 1987-07-28
ES8404322A1 (es) 1984-05-01
NZ200984A (en) 1985-01-31
FI822205L (fi) 1982-12-19
PL240483A1 (en) 1983-09-12
PL236992A1 (en) 1983-08-15
DK271682A (da) 1982-12-19
KR840000483A (ko) 1984-02-22
PL137766B1 (en) 1986-07-31
FI822205A0 (fi) 1982-06-18
EP0068739B1 (en) 1984-11-14
HU192105B (en) 1987-05-28
RO83706A (ro) 1984-03-15
CS456582A2 (en) 1985-07-16
ES520671A0 (es) 1984-05-01
RO83706B (ro) 1984-03-30
BG37226A3 (en) 1985-04-15
EP0068739A1 (en) 1983-01-05
ES8307212A1 (es) 1983-07-01
ES8404307A1 (es) 1984-05-01
FI77847B (fi) 1989-01-31
ZA824294B (en) 1983-06-29
CS241109B2 (en) 1986-03-13
KR890000622B1 (ko) 1989-03-22
IE53522B1 (en) 1988-12-07
PH23051A (en) 1989-03-10
IE821443L (en) 1982-12-18
ES520670A0 (es) 1984-05-01
PL240482A1 (en) 1983-09-12
US4513005A (en) 1985-04-23
PT75058A (en) 1982-07-01
GR76838B (fi) 1984-09-04
GB2101594B (en) 1985-12-24
GB2101594A (en) 1983-01-19
PT75058B (en) 1985-07-26
AU8500882A (en) 1982-12-23

Similar Documents

Publication Publication Date Title
FI77847C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara alkensyraderivat.
JP2510839B2 (ja) 薬剤における第一級及び第二級アミン官能基のための生物変換性プロドラッグ成分として有用な新規なｎ−（アシルオキシ−アルコキシ）カルボニル誘導体類の新規な製造方法
EP0261254B1 (en) 3,4-dihydro-4-oxo-2h-1-benzopyranyloxy alkanoic acid derivatives
KR890004127B1 (ko) 항염 작용을 갖는 피롤아세트 아미드의 제조방법
EP0061206B1 (en) 6-aminopenicillanic acid esters and their use for producing new ampicillin esters
US4461775A (en) Hydroxythioether fatty acid derivatives
KR870000275B1 (ko) 3-메틸플라본-8-카르복실산 에스테르류의 제조방법
IE57702B1 (en) P-oxybenzoic acid derivatives,methods for preparing them and their use for the preparation of medicaments with hypolipemic activity
SU923368A3 (ru) Способ получени производных бензимидазола или их солей
US4175130A (en) Oxazole- and thiazole-alkanoic acid compounds
US4469705A (en) Saturated leukotriene derivatives as antiallergens
EP0505467A1 (en) Pharmacologically active amide carboxylate derivatives
KR880001320B1 (ko) 2-시클릭아미노-2-(1, 2-벤지속사졸-3-일)아세트산 에스테르 유도체들의 제조방법
FR2460934A1 (fr) Derives d&#39;isoquinoleine contenant du soufre, procedes pour leur preparation et compositions pharmaceutiques les contenant
JP2765001B2 (ja) プロテアーゼ阻害剤
FR2600647A1 (fr) Derives de la glycine
US4275068A (en) Lipid lowering alkylene glycols and ester derivatives thereof
US4609673A (en) Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
FR2580650A1 (fr) Analogues de prostaglandines a substituant 7-oxabicycloheptane, a proprietes therapeutiques
EP1242381A2 (fr) Derives de 2-phenyl-quinoleine et leur utilisation en tant qu&#39;agent contractant des muscles lisses
SU614746A3 (ru) Способ получени аналога простагландина
US4045567A (en) 2-Alkyl-5-thiazole-carboxylic acid derivatives in hypolipemiant compositions
EP0287042B1 (en) 2-sulphinyl-acetyl-1,3-thiazolidines, their preparation and pharmaceutical compositions
JPH0676361B2 (ja) アテローム性動脈硬化症の治療または予防のための医薬組成物
SU1250170A3 (ru) Способ получени дихлоргидрата пирбутерола

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: LILLY INDUSTRIES LIMITED